Stay updated on pTVG-HP & Nivolumab in Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the pTVG-HP & Nivolumab in Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the pTVG-HP & Nivolumab in Prostate Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the efficacy of the investigational DNA vaccine, pTVG-HP, in combination with nivolumab, for decreasing serum Prostate-Specific Antigen (PSA) in patients with non-metastatic, non-castrate prostate cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:34:10.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' with additional details on eligibility criteria such as general health condition and prior treatments. The new text also includes specific inclusion and exclusion criteria for patients with adenocarcinoma of the prostate.
    Difference
    47%
    Check dated 2024-05-22T21:12:10.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:34:03.000Z thumbnail image

Stay in the know with updates to pTVG-HP & Nivolumab in Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the pTVG-HP & Nivolumab in Prostate Cancer Clinical Trial page.